Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BACE1 | P56817 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL179776 | 1.00 | BACE1 (0.33) | BACE1 | |
| SCHEMBL2992065 | 1.00 | BACE1 (0.33) | BACE1 | |
| SCHEMBL2468842 | 0.98 | BACE1 (0.32) | BACE1 | |
| SCHEMBL2463994 | 0.98 | BACE1 (0.32) | BACE1 | |
| SCHEMBL31741298 | 0.98 | BACE1 (0.32) | BACE1 | |
| SCHEMBL2469139 | 0.98 | BACE1 (0.32) | BACE1 | |
| SCHEMBL2465935 | 0.98 | BACE1 (0.32) | BACE1 | |
| SCHEMBL2471188 | 0.98 | BACE1 (0.32) | BACE1 | |
| Propene SCHEMBL11784374 | 0.89 | — | — | |
| Carbamic Acid SCHEMBL9839794 | 0.89 | ALDH1A1 (0.30) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-108752260-B | Preparation method of mitiglinide calcium intermediate | 江西济民可信药业有限公司 | 2021-07-27 | — | — | CN | disclosed |
| US-8198296-B2 | Sub-type selective azabicycloalkane derivatives | TARGACEPT, INC. (US) | 2012-06-12 | — | — | US | disclosed |
| US-20100173968-A1 | SUB-TYPE SELECTIVE AZABICYCLOALKANE DERIVATIVES | TARGACEPT, INC. (US) | 2010-07-08 | — | — | US | disclosed |
| WO-2005030718-A1 | NOVEL METHOD OF PREPARING CIS-OCTAHYDRO-ISOINDOLE | LES LABORATOIRES SERVIER (FR) | 2005-04-07 | — | — | WO | disclosed |
| WO-2005030718-A1 | NOVEL METHOD OF PREPARING CIS-OCTAHYDRO-ISOINDOLE | LES LABORATOIRES SERVIER (FR) | 2005-04-07 | — | — | WO | disclosed |
| US-4211861-A | N,N*-BISIMIDE | TECHNOCHEMIE GMBH VERFAHRENSTECHNIK (DE) | 1980-07-08 | — | — | US | disclosed |
| US-4211860-A | N,N*-BISMALEIMIDE | TECHNOCHEMIE GMBH VERFAHRENSTECHNIK (DE) | 1980-07-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100173968-A1 | SUB-TYPE SELECTIVE AZABICYCLOALKANE DERIVATIVES | CHRNB2, CHRNB4, CHRNA4 | BACE1 1619/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.